Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Sprinklr, Lowers Price Target to $11

Barclays analyst Raimo Lenschow maintains Sprinklr (NYSE:CXM) with a Overweight and lowers the price target from $12 to $11.
byBenzinga Newsdesk
November 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Raimo Lenschow maintains Sprinklr (NYSE:CXM) with a Overweight and lowers the price target from $12 to $11.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Jupiter Wellness Redeemable Digital Coupons Now Available For All Shareholders Of Record To Claim; Shareholders May Now Claim Their Digital Coupon NFT On Upstream & Redeem It For $179 Worth Of Jupiter Wellness Products Or Sell To Fans Globally On The A…

By Benzinga Newsdesk
January 23, 9:42 AM
Shareholders may now claim their digital coupon NFT on Upstream & redeem it for $179 worth of Jupiter Wellness products or sell to fans globally on the Upstream trading app JUPITER, FL / ACCESSWIRE /

JUPW

Read More

Janssen Announced Phase 3 MAGNITUDE Study Shows Trend Toward Improvement In Overall Survival in Patients With Metastatic Castration Resistant Prostate Cancer With BRCA Alterations Treated With Niraparib And Abirateron + Prednisone

By Charles Gross
October 22, 10:36 AM
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis (FA) of the Phase 3 MAGNITUDE study, in which a pre-planned multivariate analysis [MVA] showed niraparib, a

JNJ